p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
Top Cited Papers
Open Access
- 18 September 2009
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (2) , 250-259
- https://doi.org/10.1007/s00259-009-1263-1
Abstract
Purpose Immuno-PET is an emerging imaging tool for the selection of high potential antibodies (mAbs) for imaging and therapy. The positron emitter zirconium-89 (89Zr) has attractive characteristics for immuno-PET with intact mAbs. Previously, we have described a multi-step procedure for stable coupling of 89Zr to mAbs via the bifunctional chelate (BFC) tetrafluorophenol-N-succinyldesferal (TFP-N-sucDf). To enable widespread use of 89Zr-immuno-PET, we now introduce the novel BFC p-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) and compare its performance in 89Zr-immuno-PET with the reference BFC TFP-N-sucDf. Methods Three mAbs were premodified with Df-Bz-NCS and labeled with 89Zr at different pHs to assess the reaction kinetics and robustness of the radiolabeling. Stability of both 89Zr-Df-Bz-NCS- and 89Zr-N-sucDf-conjugates was evaluated in different buffers and human serum. Comparative biodistribution and PET studies in tumor-bearing mice were undertaken. Results The selected conjugation conditions resulted in a chelate:mAb substitution ratio of about 1.5:1. Under optimal radiolabeling conditions (pH between 6.8–7.2), the radiochemical yield was >85% after 60 min incubation at room temperature, resulting in radioimmunoconjugates with preserved integrity and immunoreactivity. The new radioimmunoconjugate was very stable in serum for up to 7 days at 37°C, with 89Zr release, and was equally stable compared to the reference conjugate when stored in the appropriate buffer at 4°C. In biodistribution and imaging experiments, the novel and the reference radioimmunoconjugates showed high and similar accumulation in tumors in nude mice. Conclusions The novel Df-Bz-NCS BFC allows efficient and easy preparation of optimally performing 89Zr-labeled mAbs, facilitating further exploration of 89Zr-immuno-PET as an imaging tool.Keywords
This publication has 30 references indexed in Scilit:
- Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and ChallengesBioconjugate Chemistry, 2009
- Antibodies and Antimatter: The Resurgence of Immuno-PETJournal of Nuclear Medicine, 2008
- Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclidesPublished by Elsevier ,2008
- In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor XenograftJournal of Nuclear Medicine, 2007
- Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scannerPhysics in Medicine & Biology, 2007
- Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer PatientsClinical Cancer Research, 2006
- PET Radioimmunoscintigraphy of Renal Cell Cancer Using 89Zr-Labeled cG250 Monoclonal Antibody in Nude RatsCancer Biotherapy & Radiopharmaceuticals, 2004
- Long-Lived Positron Emitters Zirconium-89 and Iodine-124 for Scouting of Therapeutic Radioimmunoconjugates with PETCancer Biotherapy & Radiopharmaceuticals, 2003
- A novel derivative of the chelon desferrioxamine for site‐specific conjugation to antibodiesInternational Journal of Cancer, 1989
- A new human cell line (FaDu) from a hypopharyngeal carcinomaCancer, 1972